专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007136680A3 3-PYRAZ0LYL-BENZAMIDE-4-ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗与相关疾病有关的5-HT2A丝氨酸受体有用的调节剂的3-氨基吡啶-4-酮，其次级胺和衍生物
公开(公告)号：WO2007136680A3
公开(公告)日：2008-01-10
申请号：PCT/US2007011789
申请日：2007-05-17
申请人： ARENA PHARM INC , TEEGARDEN BRADLEY , CHAPMAN DENNIS , DECAIRE MARC , DOSA PETER I , FEICHTINGER KONRAD , JAYAKUMAR HONNAPPA , STRAH-PLEYNET SONJA , TRAN THUY-ANH , XU JINGDONG
发明人： TEEGARDEN BRADLEY , CHAPMAN DENNIS , DECAIRE MARC , DOSA PETER I , FEICHTINGER KONRAD , JAYAKUMAR HONNAPPA , STRAH-PLEYNET SONJA , TRAN THUY-ANH , XU JINGDONG
IPC分类号： C07D413/12 , A61K31/4192 , A61K31/42 , A61K31/427 , A61K31/454 , A61P7/02 , A61P9/10 , A61P25/00 , C07D231/12 , C07D231/16 , C07D403/12 , C07D411/12
CPC分类号： C07D231/12 , A61K31/415 , C07D207/335 , C07D207/34 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病，精神病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

2. 发明申请

WO2006055734A3 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译： 3-苯基 - 吡唑衍生物作为用于治疗与其有关的疾病的5-HT2A血清素受体的调节剂
公开(公告)号：WO2006055734A3
公开(公告)日：2006-08-17
申请号：PCT/US2005041726
申请日：2005-11-17
申请人： ARENA PHARM INC , TEEGARDEN BRADLEY , XIONG YIFENG , STRAH-PLEYNET SONJA , JAYAKUMAR HONNAPPA , DOSA PETER I , FEICHTINGER KONRAD , CASPER MARTIN , LEHMANN JUERG , JONES ROBERT M , UNETT DAVID J
发明人： TEEGARDEN BRADLEY , XIONG YIFENG , STRAH-PLEYNET SONJA , JAYAKUMAR HONNAPPA , DOSA PETER I , FEICHTINGER KONRAD , CASPER MARTIN , LEHMANN JUERG , JONES ROBERT M , UNETT DAVID J
IPC分类号： C07D231/16 , A61K31/4155 , A61P29/00 , C07D231/12 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D487/08
CPC分类号： C07D231/12 , A61K31/5377 , C07D231/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D487/08
摘要： The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及调节5-HT 2A受体5-羟色胺受体活性的式（Ia）的某些3-苯基 - 吡唑衍生物及其药物组合物。其化合物和药物组合物涉及用于治疗血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房纤颤，降低血块形成风险，哮喘或其症状，激动或精神病，精神病，急性精神分裂症，慢性精神分裂症，NOS精神分裂症和相关障碍，以及睡眠障碍，睡眠障碍，睡眠障碍，睡眠障碍，精神病症状，行为障碍，药物诱导的精神病，兴奋性精神病，吉勒斯德拉图雷特综合征，，糖尿病相关病症，进行性多灶性白质脑病等。本发明还涉及与单独或一起施用的其他药剂联合治疗5-HT 2A受体5-羟色胺受体介导的病症的方法。

3. 发明申请

WO2007136875A3 ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的5-HT2A丝氨酸受体的调节剂的乙酰胺衍生物
公开(公告)号：WO2007136875A3
公开(公告)日：2008-04-10
申请号：PCT/US2007012230
申请日：2007-05-17
申请人： ARENA PHARM INC , TEEGARDEN BRADLEY , FEICHTINGER KONRAD , STRAH-PLEYNET SONJA , ULMANN BRETT , XIONG YIFENG
发明人： TEEGARDEN BRADLEY , FEICHTINGER KONRAD , STRAH-PLEYNET SONJA , ULMANN BRETT , XIONG YIFENG
IPC分类号： C07D413/12 , A61K31/415 , C07D213/12 , C07D401/12 , C07D403/12 , C07D407/14
CPC分类号： C07D231/16 , C07D231/12 , C07D401/12 , C07D405/12 , C07D417/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及某些式（Ia）的化合物及其药物组合物，其调节5-HT 2A 5-羟色胺受体的活性。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病，精神病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体相关疾病的方法。

4. 发明申请

WO2004028450A3 PROCESS OF MAKING PHENYLPYRAZOLES USEFUL AS SELECTIVE 5HT2A MODULATORS AND INTERMEDIATES THEREOF 审中-公开
标题翻译：用于选择性5HT2A调节剂的苯基吡唑的制备方法及其中间体
公开(公告)号：WO2004028450A3
公开(公告)日：2004-10-07
申请号：PCT/US0329736
申请日：2003-09-22
申请人： ARENA PHARM INC , HORNS STEFAN , RAY MAX , TEEGARDEN BRADLEY , DROUET KEITH , FEICHTINGER KONRAD , ELWELL KATIE
发明人： HORNS STEFAN , RAY MAX , TEEGARDEN BRADLEY , DROUET KEITH , FEICHTINGER KONRAD , ELWELL KATIE
IPC分类号： C07D231/16
CPC分类号： C07D231/16
摘要： The present invention relates to a process for making certain selective 5HT2A modulators of Formula (I) and the intermediates thereof: Formula (I) wherein Rl-R7 are described. Compounds of Formula (I) are useful in the prophylaxis or treatment of 5HT2A mediated diseases, such as, 5HT2A mediated platelet aggregation, asthma, agitation, degenerative diseases of the CNS and the like.
摘要翻译：本发明涉及制备式（I）的某些选择性5HT 2A调节剂及其中间体的方法：其中描述了R 1 -R 7的式（I）。式（I）化合物可用于预防或治疗5HT 2A介导的疾病，例如5HT 2A介导的血小板聚集，哮喘，兴奋，CNS退行性疾病等。

5. 发明申请

WO2009023253A3 IMIDAZO[L,2-a]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的5-HT2A丝氨酸受体的调节剂的咪唑并[L，2-a]吡啶衍生物
公开(公告)号：WO2009023253A3
公开(公告)日：2009-04-09
申请号：PCT/US2008009740
申请日：2008-08-14
申请人： ARENA PHARM INC , XIONG YIFENG , FEICHTINGER KONRAD , REN ALBERT S , ULMANN BRETT
发明人： XIONG YIFENG , FEICHTINGER KONRAD , REN ALBERT S , ULMANN BRETT
IPC分类号： C07D471/04 , A61K31/437 , A61P25/20
CPC分类号： A61K31/496 , A61K9/0019 , A61K9/0053 , A61K31/5377 , C07D471/04
摘要： rmidazo[l,2-a]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：式（Ia）的咪唑并[1,2-a]吡啶衍生物及其药物组合物，其调节5-HT2A 5-羟色胺受体的活性。化合物及其药物组合物涉及可用于治疗失眠，睡眠不良，失眠和相关睡眠障碍，血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血栓形成，哮喘或症状的方法糖尿病，糖尿病，精神病，精神病，精神分裂症，慢性精神分裂症，精神分裂症，精神分裂症，糖尿病，糖尿病，糖尿病，糖尿病，糖尿病，糖尿病，糖尿病，糖尿病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体介导的病症的方法。

6. 发明公开

KR20180031035A 5-HT2C 수용체 효능제 및 조성물 및 사용 방법 审中-公开
标题翻译： 5-HT 2C受体激动剂和组合物以及使用方法
公开(公告)号：KR20180031035A
公开(公告)日：2018-03-27
申请号：KR20187005698
申请日：2016-07-28
申请人： ARENA PHARM INC
发明人： LEHMANN JUERG , FEICHTINGER KONRAD , REN ALBERT S , SEMPLE GRAEME
IPC分类号： C07D223/16 , A61K31/55 , A61P3/04 , A61P3/10 , A61P25/08 , A61P25/32 , C07D223/32 , C07D491/052
CPC分类号： C07D223/16 , C07D223/32 , C07D491/052
摘要： 일부실시양태에서 5-HT수용체의활성을조정하는, 본원에정의된바와같은화학식 A의화합물이제공된다.일부실시양태에서체중관리, 포만감유도, 및식품섭취감소, 및비만, 항정신병제-유발체중증가, 제2형당뇨병, 프레더-윌리증후군, 담배/니코틴의존, 약물중독, 알콜중독, 병적도박, 보상결핍증후군, 및성 중독), 강박스펙트럼장애및 충동조절장애 (손톱물어뜯기및 교조증포함), 수면장애 (불면증, 분절수면구조, 및서파수면의장애포함), 요실금, 정신장애 (정신분열증, 신경성식욕부진, 및신경성폭식증포함), 알츠하이머병, 성기능장애, 발기부전, 간질, 운동장애 (파킨슨증및 항정신병제-유발운동장애포함), 고혈압, 이상지혈증, 비알콜성지방간질환, 비만-관련신장질환, 및수면무호흡의예방및 치료방법이또한제공된다.
摘要翻译：在用于调节的5-HT受体活性的一些实施方案中，式A的如本文所定义的化合物被提供有控制体重，饱食诱导，并且在一些实施例中，和食物摄入量减少，以及肥胖，抗精神病药 - 导致体重增加，2型糖尿病，预先将-Willi综合征，烟草/烟碱依赖，药物成瘾，酒精中毒，病态赌博，奖励缺陷综合症，mitseong中毒），强迫谱系障碍和冲动控制障碍（询问指甲撕裂和教育狂躁含税），睡眠障碍（失眠，睡眠结构，慢波睡眠障碍的包含），尿失禁，精神疾病（精神分裂症，神经性厌食，包括神经性贪食症），老年痴呆症，性功能障碍，勃起功能障碍，癫痫的碎片，还提供了运动障碍（帕金森病和抗精神病药物引起的运动障碍包括），高血压，血脂异常，非酒精性脂肪肝，肥胖相关的预防和治疗肾脏疾病和睡眠呼吸暂停。

7. 发明申请

WO9852917A3 GUANIDINYLATION REAGENTS 审中-公开
标题翻译：关联试剂
公开(公告)号：WO9852917A3
公开(公告)日：1999-04-22
申请号：PCT/US9810669
申请日：1998-05-21
申请人： UNIV CALIFORNIA , GOODMAN MURRAY , FEICHTINGER KONRAD , ROMOFF TODD T
发明人： GOODMAN MURRAY , FEICHTINGER KONRAD , ROMOFF TODD T
IPC分类号： C07C279/14 , C07C279/24 , C07C311/64 , C07K1/00 , C07K1/06
CPC分类号： C07C279/14 , C07C279/24 , C07C311/64 , C07K1/006 , C07K1/064 , Y02P20/55
摘要： Trisubstituted N-protected guanidines of the formulae (a, b) wherein P1, P2 and P3 are the same or different urethane protecting groups, and R is a substituted or unsubstituted alkyl or aryl group or a heterocyclic group, and salts and solvates therefore disclosed. These compounds are used as guanidinylating agents to yield N-protected guanidine derivatives.
摘要翻译：式（a，b）的三取代N-保护的胍，其中P1，P2和P3是相同或不同的氨基甲酸酯保护基，R是取代或未取代的烷基或芳基或杂环基，因此公开了盐和溶剂合物。这些化合物用作胍基化剂以产生N-保护的胍衍生物。

8. 发明专利

EA039412B1 5-HT2C РЕЦЕПТОРНЫЕ АГОНИСТЫ И КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ 未知
公开(公告)号：EA039412B1
公开(公告)日：2022-01-25
申请号：EA201890402
申请日：2016-07-28
申请人： ARENA PHARM INC
发明人： LEHMANN JUERG , FEICHTINGER KONRAD , REN ALBERT S , SEMPLE GRAEME
摘要： Изобретениеотноситсяк соединениямформулы A, гдезначениягрупп R1, R2, R3, R8, R9, X и Y определеныв формулеизобретения, которыемодулируютактивность 5-HT2C рецептора. Такжепредставленафармацевтическаякомпозициянаосновезаявленныхсоединенийи способылечениязаболеваний, опосредованныхактивностью 5-HT2C рецептора.

9. 发明专利

MA42527A AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION 未知
公开(公告)号：MA42527A
公开(公告)日：2021-04-07
申请号：MA42527
申请日：2016-07-28
申请人： ARENA PHARM INC
发明人： FEICHTINGER KONRAD , LEHMANN JUERG , REN ALBERT S , SEMPLE GRAEME
IPC分类号： A61K31/55 , A61P3/04 , C07D223/16 , C07D223/32 , C07D491/052

10. 发明专利

AU2007254244B2 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto 未知
公开(公告)号：AU2007254244B2
公开(公告)日：2013-05-02
申请号：AU2007254244
申请日：2007-05-17
申请人： ARENA PHARM INC
发明人： STRAH-PLEYNET SONJA , FEICHTINGER KONRAD , TRAN THUY-ANH , CHAPMAN DENNIS , DOSA PETER I , JAYAKUMAR HONNAPPA , DECAIRE MARC , XU JINGDONG , TEEGARDEN BRADLEY
IPC分类号： C07D413/12 , A61K31/4192 , A61K31/42 , A61K31/427 , A61K31/454 , A61P7/02 , A61P9/10 , A61P25/00 , C07D231/12 , C07D231/16 , C07D403/12 , C07D411/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式